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Safe and Allows Adequate PBSC Collection in Predicted
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or Lymphoma
Immacolata Attolico,1 Vincenzo Pavone,2 Angelo Ostuni,2 Bernardo Rossini,2
Maurizio Musso,3 Alessandra Crescimanno,3 Massimo Martino,4 Pasquale Iacopino,5
Giuseppe Milone,6 Patrizia Tedeschi,6 Sabrina Coluzzi,1 Roberta Nuccorini,1 Sara Pascale,1
Elvira Di Nardo,7 Attilio Olivieri1We evaluated the safety and efficacy of plerixafor, subsequent to disease-specific chemotherapy followed by
granulocyte-colony stimulating factor (G-CSF), in 37 multiple myeloma (MM) or lymphoma patients, who
were candidates for autologous stem cell transplantation (ASCT) predicted as poor mobilizers (PMs). Pa-
tients were identified as predicted PMs according to the history of a previously failed mobilization attempt
or the presence of$1 factors predicting an unsuccessful harvest, such as advanced disease, prior extensive
radiotherapy, or prolonged treatment, with stem cell poisons, advanced age, or extensive bone marrow in-
volvement. Plerixafor (0.24 mg/kg) was administered subcutaneously for up to 3 consecutive days while con-
tinuing G-CSF for 9 to 11 hours before the planned apheresis. Plerixafor administration was safe and no
significant adverse events were recorded. We observed a median 4-fold increase (range: 1.4-32) in the num-
ber of circulating CD341 cells following plerixafor compared with baseline CD341 cell concentration (from
a median of 5 cells/mL, range: 1-32, to a median of 32 cells/mL, range: 6-201). Twenty-seven of the 37 patients
(14 of 17 with MM and 13 of 20 with lymphoma) had$2106 CD341 cells/kg collected in 1-3 apheretic pro-
cedures. Of the 27 patients rescued with plerixafor, 24 (13 MM, 11 lymphoma) have been transplanted with
plerixafor-mobilized peripheral blood stem cells, showing a rapid and durable hematologic recovery. Our
results suggest that the addition of plerixafor to G-CSF after disease-oriented chemotherapy is safe and
allows for a satisfactory harvest in order to perform a safe ASCT, in a relevant proportion of lymphoma
and MM patients considered to be PMs.
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Autologous stem cell transplantation (ASCT) is
a mainstream therapy for patients with lymphoma or
multiple myeloma (MM); however, 5% to 40% of
MM or lymphoma patients fail to mobilize adequate
numbers of peripheral blood stem cells (PBSCs), and
thus cannot undergo a planned ASCT [1]. Over the
past decade, different criteria have been proposed to
define a successful CD341 cell mobilization, leading
to an adequate apheresis yield. The current minimal
thresholdCD341 cell dose needed for the achievement
of a fast, complete, and stable long-term engraftment,
has been determined as $2-2.5106 CD341 cells/kg
for a single ASCT [2-8]. Reinfusion of higher doses
of CD 341 cells has been associated with reductions
in the duration of hospital stay and transfusion
support requirements [9]. Moreover, in some studies,
lymphoma patients transplanted with .2106 CD341241
242 Biol Blood Marrow Transplant 18:241-249, 2012I. Attolico et al.cells/kg showed significantly better survival rates [10].
The 2 most commonly used mobilization regimens
are the cytokine granulocyte-colony stimulating factor
(G-CSF) and chemotherapy followed by G-CSF. The
latter is reportedly associated with better harvests
[11-14], even though it did not seem to reduce the
percentage of mobilization failures [4].
Plerixafor, a novel CXCR4 inhibitor, is effective in
mobilizing PBSCs, particularly when used in combina-
tion with G-CSF [15], and it reportedly augments the
mobilization of the CD341 cells from bone marrow
(BM) into peripheral blood (PB) when given
after 4 days of G-CSF. Studies in non-Hodgkin
lymphoma (NHL) and MM patients showed that the
combination of G-CSF and plerixafor resulted in a
significant increase in the CD341 cell yield after apher-
esis compared with the administration of G-CSF alone
[16,17]. Moreover, plerixafor administration combined
with G-CSF allowed for the progression to ASCT in
a relevant proportion of lymphoma and MM patients,
and for the achievement of rapid and sustained
neutrophil (PMN) and platelet (PLT) engraftment of
the mobilized PBSCs [18].
Consequently, plerixafor represents a valuable
option for MM or lymphoma patients who mobilize
poorly. Unfortunately, there are still some controver-
sies concerning the identification of poor mobilizers
(PMs). Data regarding the identification of PMs and
the main factors affecting mobilization ability in MM
and lymphoma patients derive from retrospective stud-
ies and are often difficult to analyze [1,4].Nevertheless,
early identification of PMs is an important issue that
can prevent mobilization failures and designate these
subjects for ‘‘ad hoc’’ mobilization strategies.
Over the past decade, some retrospective studies
have confirmed the efficacy of plerixafor administration
in combination with G-CSF inMM and lymphoma pa-
tients, although scarce information is available regard-
ing the efficacy of plerixafor when associated with
chemotherapy plus G-CSF. Therefore, we addressed
this issue and assessed the safety and efficacy of plerixa-
for administered after chemotherapy followed by G-
CSF in a population of MM and lymphoma patients
identified as PMs, using a set of standardized criteria.PATIENTS AND METHODS
Study Design
MM and lymphoma patients, according to the lo-
cal policy of 5 italian centers, were enrolled in this pro-
spective observational cohort study. Patients received
plerixafor as compassionate use, on the basis of the
presence of at least 1 of the following standardized
criteria devised to identify patients as predicted PMs:
1. Mobilization failure, defined as evidence of a previ-
ously failed attempt to collect $2106 CD341cells/kg after both G-CSF alone and chemotherapy
followed by G-CSF. This criterion included both
patients who did not undergo apheresis, because of
an unsatisfactory peak of circulating CD341 cells
(eg,\10/mL) and those who underwent at least 3
consecutive apheresis procedures with total yields
#2106 CD341 cells/kg [1,4].
2. Presence of$1 adverse factors for PBSC mobiliza-
tion, such as advanced disease, prior treatment with
extensive radiotherapy (including BM-bearing tis-
sues), prolonged chemotherapy ($2 courses), past
exposure to stem cell poisons (SCP) (eg, fludara-
bine, lenalidomide and alkylating agents such as
melphalan), advanced age (.65 years old), or exten-
sive BM involvement (.30%) before mobilization.
The main endpoint of the study was to assess
whether the use of plerixafor after disease-specific che-
motherapy followed by G-CSF would be safe and
would allow adequate PBSC collection in MM and
lymphoma patients considered to be predicted PMs
according to the previously mentioned criteria. Sec-
ondary endpoints evaluated were: the increase in
CD341 cell count in PB after plerixafor in the different
groups of patients; median number of apheresis days
needed to collect the target dose of CD341 cells;
percentage of patients able to undergo ASCT; engraft-
ment kinetics after reinfusion of plerixafor-mobilized
PBSC; and the overall outcome of the autografted
patients.
The enrollment of a minimum of 24 and a maxi-
mum of 42 patients was planned to allow the evaluation
of safety. The study was conducted in compliance with
theDeclaration of Helsinki andGoodClinical Practice
guidelines and was approved by the institutional review
board of each center. All patients provided written
informed consent.
Study Patients
Between April 2009 and May 2010, a total of 37
(17 MM, 20 lymphoma) patients were enrolled
(22 males, 15 females). The median age was 58 (range:
20-74). The demographic details are reported in
Table 1a,b. All 37 patients fulfilled $1 criteria for
the identification of predicted PMs: Most (30) had ad-
vanced-stage disease, and 28 had received at least 2:
prior chemotherapy courses (median 2, range:
2-4). A previous administration of SCP was docu-
mented in 17 patients and, most important, 25 of the
37 patients had previously failed at least 1 mobilization
attempt (in 3 cases $2 attempts). Twelve patients (5
MM, 7 lymphoma) did not fail a previous mobilization
attempt, but were included in the study on the basis of
meeting 1 or more of the remaining criteria. Specifi-
cally, of the 5 MM patients, 1 had received previous
extensive spinal radiotherapy, 2 lenalidomide (for 9
and 4 months, respectively), 1 ASCT with high-dose
Table 1 (a,b). Main Characteristics of MM (a) and Lymphoma (b) Patients before Mobilization
(a)
MM Patients
Age
(years) Sex
Disease Stage
at Diagnosis
Number
of Prior CHT Previous SCP Previous RX Ther
Failure of Previous
Mobilization
Disease Status at
PBSC Mobilization
1 62 F IIIA 2 Y N Y nCR
2 60 M IIIA 1 N N Y PR
3 61 F IIIA 1 N N Y PR
4 66 M IIIA 1 Y N Y PR
5 57 F IIIA 3 Y N Y PR
6 67 F IIIB 4 Y N Y PD
7 63 M IIA 1 N N Y PR
8 58 F IIIA 2 N Y N CR
9 59 M IIIB 2 Y N Y PR
10 59 M IIIB 2 Y N Y PR
11 52 F IIIA 2 Y N N VGPR
12 64 F IIA 3 Y N Y CR
13 65 M IIIA 1 N N N VGPR
14 57 F IIIA 2 Y N Y PR
15 57 F IIIA 3 Y N N PD
16 53 M IIA 3 Y N N PR
17 53 F IIIA 2 N N Y VGPR
(b)
Lymphoma
Patients
Age
(years) Sex
Disease Stage
at Diagnosis
BM Infiltrate
$30%
Number of
Prior CHT Previous SCP
Previous
RX Ther
Failure of Previous
Mobilization
Disease Status at
PBSC Mobilization
1 47 M IV Y 1 N N Y PR
2 52 F IV Y 3 N N Y RD
3 58 M IV N 2 N N Y REL
4 50 M IV Y 2 N N N CR
5 53 M III N 2 Y N N REL
6 54 M IV Y 3 Y N N REL
7 68 M IV Y 2 N N Y PR
8 71 M IVA Y 2 N N Y SD
9 50 M IVA Y 2 Y N Y CR
10 52 M IVE N 1 Y N Y CR
11 52 F IIA Y 3 Y Y Y CR
12 54 F IVA Y 1 Y N Y CR
13 74 M IIIA Y 2 N N Y PR
14 54 M IVB Y 2 N N N RD
15 60 M IVA Y 3 N N N VGPR
16 54 M IIB N 1 N Y Y CR
17 64 F IIA N 3 N N N REL
18 20 M IIIA N 3 N N N REL
19 72 F IISB N 3 N N Y PR
20 58 M IVSB Y 2 N N Y PR
MM indicates multiple myeloma; BM, bonemarrow; N, number; CHT, chemotherapy; SCP, stem cell poison; RXTher, radiotherapy; PBSC, peripheral blood
stem cell; CR, complete remission; PR, partial response; VGPR, very good partial response; SD, stable disease; RD, resistant disease; REL, relapse.
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and Lymphoma Patientsmelphalan 200 mg/m2, and the remaining had an ad-
vanced disease with extensive BM involvement and ad-
vanced age. Among the 7 lymphoma patients, 2 had
Hodgkin’s lymphoma (HL) and were heavily pre-
treated ($2 full courses of chemotherapy), whereas 5
had NHL: 2 had received $6 cycles of chemotherapy
including fludarabine (1 also had an extensive BM lym-
phoma involvement), and 3 had indolent lymphoma
with an extensive (.30%) BM involvement (1 had
also received 3 full courses of chemotherapy).Mobilization Regimens
Disease-specific mobilization regimens were
planned according to the local institutional guidelines.The most frequent mobilization regimens were
cytoxan at an intermediate dose in 12 MM patients
and DHAP [19] in 13 lymphoma patients; a minority
of patients received VP16 at a high dose [20] or
HyperC-VAD [21]. The details of the mobilizing
chemotherapy are shown in Table 2. G-CSF at 5 to
10 mg/kg/day was administered subcutaneously, start-
ing at 48 to 96 hours after the end of chemotherapy and
continued until the last apheresis day.
Plerixafor administration was planned in order to
reach at least 2-2.5106 CD341 cells/kg (within #3
consecutive apheresis days) for patients scheduled for
a single ASCT. On the other hand, a minimum thresh-
old of 4-5106 CD341 cells to be collected was
planned for the MM patients who were candidates
Table 2. Details of Mobilization Schedules, White Blood Cells Count, and CD34+ Cells Kinetics and Collections in MM and Lym-
phoma Patients
Characteristics MM Lymphoma
CHT mobilizing regimen HD-CTX: 12
VP16: 3
Others: 2
DHAP: 13
HyperCVAD: 2
VP16: 2
Others: 3
Plerixafor injections:, median (range) 2 (1-3) 1 (1-2)
WBC before plerixafor (103/mL):, median (range) 17 (2.1-68) 8.15 (1.4-61)
WBC 11 hours after plerixafor (103/mL), median (range) 26.5 (3.5-79) 16.1 (7.2-65)
CD34+ before plerixafor (103/mL):, median (range) 6 (2-32) 5 (0-26)
CD34+ 11 hours after plerixafor (103/mL): median (range) 33 (6-201) 29 (0-116)
Fold increase CD34+ count:, median (range) 4 (2-25) 3 (0-32)
Total number of CD34+ cells collected (106/kg):, median (range) 4.9 (0-15.2) 2.65 (0-8.2)
Total number of apheresis: median (range) 2 (0-3) 1 (0-2)
MM indicates multiple myeloma; CHT, chemotherapy; HD-CTX, high-dose cytoxan; DHAP, dihydroxyacetone phosphate; CVAD, cyclophosphamide,
vincristine, doxorubicin; WBC, white blood cell.
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Europe BV, Naarden, the Netherlands) was added to
G-CSF under a compassionate use program. The
drug was administered subcutaneously at 0.24 mg/
kg/day for up to 3 days the evening before the planned
leukapheresis (from 9-11 hours before starting the
procedure). The patients received a median of 2 pler-
ixafor administrations (range: 1-3) after mobilization.
PBCS Collection and Transplantation
The start of PBSC collections was generally
planned when the CD341 cell count in the PB was
$5/mL after plerixafor administration. The mobiliza-
tion attempts never reaching the threshold of
CD341 $10/mL in the PB, after at least 3 consecutive
days of plerixafor administration, or failing to yield a
total of$2106 CD341 cells/kg, were considered fail-
ures. CD341 cell count was determined using the sin-
gle platform as recommended by the International
Society of Hematotherapy and Graft Engineering
(ISHAGE) protocol, combined with a viability test
performed with 7-actinomycin D [22]. Double-
volume leukapheresis or large-volume leukapheresis
(ie, 3-blood volume 615%) was used according to in-
stitutional guidelines. A maximum of 3 apheresis days
was performed for each patient.Table 3. Comparison of Characteristics Influencing the
Mobilization Ability in MM and Lymphoma Patients
Characteristics MM Lymphoma P
Age (median) 59 (SD 4.556) 54 (SD 7.865) .123
Sex (M/F) 7/10 15/5 .08
Previous chemotherapy courses
(median)
2 (SD 0.899) 2 (SD 0.745) .637
SCP (Y/N) 11/6 6/14 .075
RX ther (Y/N) 1/16 2/18 1
Previous mobilization failure (Y/N) 12/5 13/7 .99
PB CD34+ cells* before plerixafor
(median)
6 (SD 11.425) 5.5 (SD 7.048) .718
MM indicates multiple myeloma; SCP, stem cell poison; RX ther,
radiotherapy; PB, peripheral blood; SD, Standard deviation.
*CD34+ cells/mL in PB before the first plerixafor administration.The collected PBSCs were reinfused after myeloa-
blative conditioning consisting of high-dose melpha-
lan 200 mg/m2 for MM patients and of diverse
chemotherapy-based regimens for lymphoma patients
(Table 5). Posttransplantation G-CSF was adminis-
tered at 5 mg/kg/day, starting 3 to 7 days after PBSC
reinfusion, according to the local institutional policy,
up to PMN recovery. All patients were hospitalized
in single rooms with HEPA filters and positive air
pressure until neutrophil engraftment. The antimicro-
bial prophylaxis consisted of the administration of oral
quinolones and fluconazole at 400 mg/day. All patients
received empirical antibiotic therapy in case of fever
.38C and the transfusion support consisted of irradi-
ated blood products. Time to PMN and PLT recovery
were defined as the number of days needed to achieve
an absolute neutrophil count (ANC) higher than
0.5103/mL (first of 3 consecutive days) and an unsup-
ported PLT count higher than 20103/mL and
50103/mL.
Statistical Methods
The 2 populations of MM and lymphoma patients
were compared using the Mann-Whitney U test for
the continuous variables and cross-tab tests for the dis-
crete variables because of the small sample size. The
Mantel-Haenszel Common Odds Ratio Test was em-
ployed for the dichotomized variables. Mobilization
results in the 2 populations (CD341 peak, CD341
fold increase, CD341 cumulative harvest, and percent-
age of patients failing to achieve $2106 harvested
CD341/kg) were compared using the Mann-
Whitney U test for the continuous variables; cross-
tab tests were used for the discrete variables. Similarly,
the Mantel-Haenszel Common Odds Ratio Test was
employed for the dichotomic variables. Engraftment
kinetics in the 2 populations (eg, median number to
achieve an ANC higher than 0.5103/mL, first of the
3 consecutive days, and an unsupported PLT count
higher than 20103/mL and 50103/mL) were
compared using the Mann-Whitney U test [23].
Table 4. Comparison of Mobilization Ability, Harvest, and Engraftment in the Two Populations (MM and Lymphoma Patients)
MM Lymphoma P
PB CD34+ cells* after plerixafor (median) 33 (SD 45.499) 31 (SD 26.946) .437
Fold increase (median) 4 (SD 5.985) 3 (SD 7.563) .485
CD34+ harvested (106/kg) (mean) 6.36 (SE 1.121) 3.8 (SE 1.063) .03
Number of leukapheresis (median) 2 (SD 0.845) 1 (SD 0.514) .059
% of pts failing to harvest $2  106 CD34/kg 18 35 .24
Days for PMN >500 (median) 12 (SD 1.832) 14 (SD 3.795) .076
Days for PLT >20,000 (median) 15 (SD 1.809) 18 (SD 22.033) .037
Days for PLT >50,000 (median) 18 (SD 7.648) 30 (SD 50.904) .011
MM indicates multiple myeloma; PB, peripheral blood; pts, patients; PMN, neutrophils; PLT, platelets; SD, standard deviation, SE, standard error.
*CD34+ cells/mL 9 to 11 hours after plerixafor administration, before the first apheresis.
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The 2 populations of MM and lymphoma patients
were well matched for the main clinical characteristics
influencing their mobilization ability (Table 3). Mobi-
lization with chemotherapy followed by G-CSF and
plerixafor was well tolerated, and we did not observe
any grade 3-4 extrahematologic toxicities. Only
1 patient developed a fever of unknown origin during
the neutropenic phase. We did not observe any signifi-
cant laboratory abnormalities or any worsening of liver
or renal function during plerixafor administration.
The median value of the white blood cell count be-
fore plerixafor administration was 9103/mL (range:
1.4-68103/mL) and increased to 19103/mL (range:
3.5-79103/mL) posttreatment.
Twenty-seven of the 37 patients who received
plerixafor were successfullymobilized, collecting ame-Table 5. Disease Status after Mobilization and before ASCTand O
Transplanted
Patients Disease
Response after
Chemomobilization
Conditioning
Regimens
1 HL CR FEAM [24]
2 HL SD FEAM [24]
3 HL PR BEAM [25]
4 NHL PR FEAM [24]
5 NHL CR FEAM [24]
6 NHL PR FEAM [24]
7 NHL SD FEAM [24]
8 NHL CR BEAM [25]
9 NHL CR TEAM [26]
10 NHL CR Thio-Mel
11 NHL PR BEAM [25]
12 MM nCR Mel 200
13 MM PR Mel 200
14 MM VGPR Mel 200
15 MM PR Mel 200
16 MM PR Mel 200
17 MM PR Mel 200
18 MM CR Mel 200
19 MM VGPR Mel 200
20 MM CR Mel 200
21 MM VGPR Mel 200
22 MM PR Mel 140
23 MM PR Mel 200
24 MM PR Mel 140
Summary
median (range)
3 HL/8 NHL/13 MM
–
8 CR, nCR/14 PR,
VGPR/2SD
–
13 HDM/11 othe
–
ASCT indicates autologous stem cell transplantation; MM,multiple myeloma; HD
HL, Hodgkin’s lymphoma; NHL, non-Hodgkin lymphoma; CR, complete remi
response; nCR, near complete remission; NR, not reached; NE, not evaluabledian of 5.4106 CD341 cells/kg (range: 2-15.2) over
a maximum of 3 apheresis days. Ten patients failing
the mobilization were considered not eligible for
ASCT and received alternative treatments.
The median value of the circulating CD341 cells/
mL before plerixafor administration was 5 (range: 0-32)
and did not show any significant differences between
MMand lymphoma patients (P5 .718). After plerixafor
administration and before the first apheresis, themedian
number of circulating CD341 cells was 32 (range: 0-
201), with a median 4-fold increase (range: 1.4-32). A
comparison of the mobilization results after plerixafor
in MM and lymphoma patients is shown in Table 4.
We did not observe statistical differences between the
2 populations in terms of CD341 peak, CD341 fold in-
crease, or in the number of apheresis days, but we did
find a significantly better harvest (in terms of totalutcome in the 24 MM and Lymphoma Patients
ANC
>500/mL
PLT >20
x 103/mL
PLT >50
x 103/mL
Response
at Day +90
Status at
Day +90
12 17 19 CR A
13 18 30 NE NE
14 21 38 PR A
17 22 36 CR A
14 17 22 CR A
20 88 NR PR A
14 34 NR NE NE
10 9 26 CR A
23 10 24 CR A
16 30 180 CR A
12 15 33 PR A
11 15 18 nCR A
11 11 16 PR A
16 16 22 VGPR A
13 13 16 PR A
15 15 20 PR A
13 15 15 PR A
11 14 20 CR A
11 13 30 VGPR A
– – – – D
11 15 18 nCR A
12 18 40 PR A
12 NR NR NR A
15 15 15 PR A
r –
13 (10-23)
–
15 (9-88)
–
22 (15-180)
9 CR, nCR/11
PR, VGPR
21 A/2 NE/1 D
-
M, high dosemelphalan; ANC, absolute neutrophil count; PLT, platelets;
ssion; PR, partial response; SD, stable disease; VGPR, very good partial
; A, alive; D, dead.
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tients (mean 6.36106/kg vs 3.8106/kg; P5 .03).
The percentage of successful collections after mo-
bilization with chemotherapy followed by G-CSF plus
plerixafor was 73%: 65% in lymphoma patients and
82% in MM patients. At a confidence level of 95%,
the percentage of patients failing to achieve $2106
CD341/kg was significantly higher in the lymphoma
patients (data not shown).
Overall, of the 27 patients with satisfactory harvests
($2106/kg), 24 (65%)wereautografted; the3 remain-
ing patients with satisfactory collections were not able
to undergo ASCT because of rapid disease progression.
In detail, 14 of 17 MM patients had satisfactory
harvests ($2106 CD341 cells/kg) and 13 received
ASCT; 13 of 20 lymphoma patients (8 of 15 NHL
and 5 of 5 HL) had satisfactory harvests and 11 under-
went ASCT (8 of 8 NHL and 3 of 5 HL).
After mobilization, 9 of the 11 lymphoma patients
who received ASCT were in complete remission or
partial remission (PR), whereas all 13 MM patients
achieved equal to or greater than PR before ASCT.
All but 3 patients showed rapid and complete engraft-
ment. Of the 3, 1 MM patient died of sepsis during the
aplastic phase, 1 NHL patient showed both delayed
PMN and PLT recovery reaching ANC $500/mL on
day 20 and PLT$20,000 on day 88, without reaching
PLT count $50,000, and the third patient reached
ANC$500/mL on day 23 but showed a quick PLT re-
covery. The latter 2 patients are alive and in PR or
complete remission, respectively, at last follow-up.
The differences in PMN engraftment kinetics
were not significant between the 2 populations. A
median of 12 days (range: 11-16, SD 5 1.832) was
observed in the MM patients and 14 days (range: 10-
23, SD 5 3.795) in the lymphoma patients
(P 5 .076). In contrast, a significant difference was
observed for PLT engraftment, with a median of
18 days to reach a PLT count $20,000/mL (range:
9-88, SD 5 22.033) in the lymphoma patients versus
15 days (range: 11-18, SD5 1.809) in theMMpatients
(P 5 .037). It took 30 days to reach a PLT count
$50,000/mL (range: 19-180, SD5 50.904) in the lym-
phoma patients versus 18 days (range: 15-40, SD 5
7.648) in the MM patients (P 5 .011).
After a minimum follow-up of 90 days after ASCT,
21patients (12MMand9 lymphomapatients)were alive
and evaluable for response,with11MMpatients consid-
ered responders (equal to or greater than PR) and 1with
refractory disease, whereas 6 lymphomapatientswere in
complete remission and 3 in PR (Table 5).DISCUSSION
In the present study, we report the results of differ-
ent mobilization regimens, based on chemotherapy,followed by G-CSF and plerixafor in a group of
37 MM and lymphoma patients who were candidates
for ASCT. These patients were prospectively identi-
fied as predicted PMs based on uniformly standardized
criteria. Most of these criteria were previously used in
large studies with plerixafor [16,17,27], particularly in
patients with a history of a previous mobilization
failure, which is generally intended as the failure to
collect at least 2106 CD341 cells/kg [4,18,28] or to
reach a peak $10-15 CD341 cells/mL in PB after
mobilization [1].
Indeed, 25 of the 37 patients enrolled in our study
had at least 1 previously failed mobilization attempt. In
the remaining 12 patients, the identification of pre-
dicted PMs was based on a series of criteria that were
demonstrated to negatively affect mobilization in
large retrospective studies, such as: advanced age
[29-31], advanced stage disease [32,33], extensive BM
involvement, or previous heavy/prolonged treatment,
including extensive radiotherapy or SCP [34-38].
This is the fourth report on the use of plerixafor
after chemotherapy followed by G-CSF. In the first
report, 44 patients with lymphoma or MM received
plerixafor after different kinds of chemotherapy sched-
ules plus G-CSF [39]. This study, however, did not
focus on the potential of plerixafor in PMs. In the sec-
ond study, 13 patients received plerixafor after chemo-
therapy plus G-CSF, based on previous mobilization
failure and evidence of a minimum number of circulat-
ing CD341 cells [40]. An extensive evaluation of the
ASCT outcome after plerixafor-mobilized PBSC rein-
fusion was not reported in either of the 2 studies. In
a recentGerman survey, 47 patients received plerixafor
combined with G-CSF plus chemotherapy, yielding
a median of 3.28106 CD341 cells/kg. A good pro-
portion of these patients (67%) were able to proceed
to ASCT, achieving a timely and stable engraftment
[41].
Our data confirm that the addition of plerixafor to
G-CSF after chemotherapy is safe, suggesting that this
strategy can effectively rescuemost PMs candidates for
ASCT and who previously failed a mobilization
attempt, in a similar proportion to that observed in
patients receiving plerixafor1G-CSF without chemo-
therapy [27,42].
We observed a remarkable multiple-fold increase
(median value: 4) in the number of circulating
CD341 cells after plerixafor administration, both in
MM and lymphoma patients. In addition, our results
confirm the safety profile of plerixafor following che-
motherapy. Of note, plerixafor administration did
not induce any significant alterations in platelet values
or hemoglobin levels during the postchemotherapy
period before PBSC collection. Of note, 65% of PM
patients with high-risk disease were rescued with
ASCT and the outcome was good both in terms of en-
graftment and in terms of clinical response.
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and Lymphoma PatientsHistorically, several strategies to collect PBSC
have been reported, but chemotherapy plus G-CSF,
or G-CSF alone, are the most widely used.
Cytokine-only mobilization, with G-CSF instead of
granulocyte macrophage-colony stimulating factor, is
less toxic, easier to plan, and requires less time (5-7
days). Therefore, it is considered potentially more
cost effective. Chemotherapy-based mobilization re-
quires a longer period of time (10-15 days) and is less
predictable, requiring additional monitoring and care-
ful scheduling to ensure that the beginning of the col-
lections coincides with peak CD341 cells levels. This
strategy may be associated with relevant toxicities,
such as infections, and requires greater resource utili-
zation. Nevertheless, mobilization with chemotherapy
remains an important option because of a greater yield
of PBSCs for transplantations [43] and because of the
additional cytoreductive effect described in several
previous reports [44,45].
Several studies have investigated the effect of pler-
ixafor added to G-CSF in cytokine-only mobilization
strategies, especially in patients at the second mobili-
zation challenge. However, very few studies have eval-
uated the effect of plerixafor after chemotherapy plus
G-CSF. In a large study, remobilization strategy
without plerixafor in MM and lymphoma patients,
who previously failed to collect at least 2106
CD341 cells/kg, resulted in rescues of no more than
23% patients, with 30% failing to pool sufficient
numbers of stem cells from both collections [4].
Calandra et al. [18] mobilized, with plerixafor plus
G-CSF, 115 patients defined as PMs by a previously
failed attempt, low peripheral blood CD341 cell
counts, or low apheresis yields (usually \2106
CD341 cells/kg). Tricot et al. [28] used plerixafor
plus G-CSF in 20 patients identified as both proven
PMs (in cases of previous mobilization failure) and
predicted PMs, according to different criteria, such
as history of extensive chemotherapy premobilization,
PLT count\100 103/mL, and CD341 peak\12/mL
after mobilization. Indeed, the use of plerixafor has
been recently considered in patients without prior his-
tories of mobilization failure, but with characteristics
that adversely affect CD341 yield [46].
In our study, the combination of chemotherapy
followed by G-CSF plus plerixafor allowed for
successful harvests in 73% of patients. This highly
successful mobilization rate in these heavily pretreated
patients, associated with the very low toxicity of the
mobilization procedure, suggests that chemotherapy
followed by G-CSF plus plerixafor can represent
a safe and effective strategy in this subset of patients.
However, this study was not specifically designed to
show any benefits of using plerixafor after chemother-
apy plus G-CSF over the combination of G-CSF plus
plerixafor. Our preliminary data suggest that, by pool-
ing the total apheresis collections, MM patientscollected significantly higher CD341 cell doses than
the lymphoma patients. However, the CD341 increase
rates after plerixafor did not significantly differ,
suggesting that plerixafor is equally effective in the 2
populations. Moreover, the higher CD341 cell dose
reinfused in the MM patients did not translate into
faster PMN recovery, whereas a significantly faster
PLT recovery was observed in the MM patients.
Last, the administration of plerixafor after chemother-
apy plus G-CSF can offer the potential advantage of
better disease control, especially in patients with
relapsed aggressive lymphoma. This can translate
into a higher percentage of patients eligible for
ASCT [47], compared with patients mobilized with
G-CSF and plerixafor alone, in whom the lack of
disease debulking could potentially lead to ASCT
failures in some cases.
In conclusion, our data encourage the use of
plerixafor after chemotherapy followed by G-CSF in
lymphoma or MM patients identified as predicted
PMs. The patients underwent this mobilization regi-
men without major toxicities, and most of them
achieved minimum safe doses of CD341 cells for
ASCTwithin a few days of apheresis and rapid engraft-
ment. This strategy needs to be evaluated in a larger
group of lymphoma and MM patients, who are identi-
fied as PMs according to well-standardized criteria and
receiving homogeneous mobilizing protocols.ACKNOWLEDGMENTS
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